Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors
- 15 June 1995
- Vol. 75 (12) , 2897-2903
- https://doi.org/10.1002/1097-0142(19950615)75:12<2897::aid-cncr2820751217>3.0.co;2-r
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Primary Chemotherapy for Stage II Nonseminomatous Germ Cell Tumors of the TestisJournal of Urology, 1994
- Comparison between Clinical and Pathological Staging in Low Stage Nonseminomatous Germ Cell Testicular TumorsJournal of Urology, 1992
- Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?Journal of Clinical Oncology, 1992
- Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer?Journal of Clinical Oncology, 1991
- Staging Relationships and Outcome in Early Stage Testicular Cancer: A Report From the Testicular Cancer Intergroup StudyJournal of Urology, 1991
- Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.Journal of Clinical Oncology, 1989
- Stage II Nonseminomatous Germ Cell Tumors of the Testis: An Analysis of Treatment Options in Patients with Low Volume Retroperitoneal DiseaseJournal of Urology, 1988
- Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular CancerNew England Journal of Medicine, 1987
- No Adjuvant Chemotherapy in Selected Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumors of the TestisJournal of Urology, 1984
- Adjuvant Chemotherapy in Non-Seminomatous Testis Cancer: “Mini-Vab” Regimen: Long-Term FollowupJournal of Urology, 1981